Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density.
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 8:30ET Import Export Price Indexes; 9:00ET: Fed’s Harker speaks on the 2023 economic outlook; 10:00ET U. of Mich. Sentiment; 3:15ET Biden to discuss Bidenomics TODAY’S HIGHLIGHTS: Jeff Bezos will pay $79 million for a seven-bedroom mansion in South FloridaHamas called for a
NOVATO, Calif., Oct. 09, 2023 Ultragenyx Pharmaceutical Inc. today announced that data from its ongoing late-stage program evaluating setrusumab in osteogenesis imperfecta will be presented.